News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko News Releases 2007

October 30, 2007
Kyowa Hakko Kogyo Co., Ltd.Fiscal 2007 First Half ResultsPDF file:New window opens(231KB)
October 29, 2007
Kyowa Hakko Interim Operating Income up 25.2%PDF file:New window opens(32KB)
October 22, 2007
Strategic Alliance Between Kyowa Hakko Group and Kirin GroupPDF file:New window opens(569KB)
October 22, 2007
Notification with Respect to the Conclusion of the Share Exchange Agreement
Between Kyowa Hakko Kogyo Co., Ltd. and Kirin Pharma Company, Limited
PDF file:New window opens(331KB)
October 22, 2007
Kirin Holdings Company, Limited's Press Release:
“Notification with Respect to Commencement of Tender Offer for Shares of Kyowa Hakko Kogyo Co., Ltd.”
PDF file:New window opens(497KB)
October 22, 2007
Notification with Respect to Approval of Tender Offer For Shares of Kyowa Hakko Kogyo Co., Ltd.PDF file:New window opens(57KB)
October 22, 2007
Notification with Respect to the Strategic Alliance Between Kyowa Hakko Group and Kirin Group Centering Around the Integration of Kyowa Hakko Kogyo Co., Ltd. and Kirin Pharma Company, LimitedPDF file:New window opens(150KB)
October 22, 2007
Strategic Alliance Between Kyowa Hakko Group and Kirin Group
Maximizing Synergy Through an Alliance Centered Around the Pharmaceutical Business
PDF file:New window opens(80KB)
July 27, 2007
Kyowa Hakko licensed to BioWa (wholly owned subsidiary in US),
a novel antibody engineering technology (COMPLEGENT)
for the efficacy enhancement of therapeutic antibodies
July 27, 2007
Kyowa Hakko Three-month Net Sales up 10.8%;
Raises profit forecasts
PDF file:New window opens(25KB)
April 27, 2007
Kyowa Hakko Fiscal 2006 Operating Income up 20.2%PDF file:New window opens(73KB)
April 27, 2007
Submission of New Drug Application
for Istradefylline(KW-6002),
an investigational anti-Parkinson's disease drug
April 27, 2007
Kyowa Hakko in-licenses ARQ 197,
an anticancer agent in clinical development,
from the US company ArQule.
March 6, 2007
Kyowa Hakko Kogyo Co., Ltd. licenses
its in-house developed antibody KW-2871
targeting malignant melanoma to
Life Science Pharmaceuticals in the US.

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.



To Page Top